Compare SLDB & ADAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLDB | ADAM |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 623.0M | 702.0M |
| IPO Year | 2017 | 2003 |
| Metric | SLDB | ADAM |
|---|---|---|
| Price | $6.43 | $4.86 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 7 |
| Target Price | ★ $18.71 | $11.17 |
| AVG Volume (30 Days) | 1.2M | ★ 1.6M |
| Earning Date | 11-04-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 25.26% |
| EPS Growth | 34.97 | ★ 196.49 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,094,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.65 | $4.60 |
| 52 Week High | $11.45 | $10.36 |
| Indicator | SLDB | ADAM |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 19.95 |
| Support Level | $6.25 | N/A |
| Resistance Level | $6.58 | $9.36 |
| Average True Range (ATR) | 0.50 | 0.31 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 30.12 | 8.74 |
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing, and managing mainly mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit-sensitive single-family and multi-family assets.